Corbus Pharmaceuticals (CRBP) Receives a Buy from Nomura


Nomura analyst Christopher Marai maintained a Buy rating on Corbus Pharmaceuticals (CRBP) yesterday and set a price target of $12.00. The company’s shares closed last Wednesday at $6.46.

According to TipRanks.com, Marai is a 4-star analyst with an average return of 3.8% and a 50.7% success rate. Marai covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Deciphera Pharmaceuticals, and Alexion Pharmaceuticals.

Corbus Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $21.33, which is a 207.3% upside from current levels. In a report issued on May 11, Oppenheimer also assigned a Buy rating to the stock with a $28.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $7.80 and a one-year low of $3.29. Currently, Corbus Pharmaceuticals has an average volume of 1.03M.

Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CRBP in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company’s lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts